Blog
Dupilumab: Transforming Immunotherapy and Skin Disease Management
What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
…
1st Feb 2025
Inebilizumab: Advancing Research and Clinical Applications
What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
…
1st Feb 2025
Naratuximab: Redefining Cancer Therapy with Precision Medicine
Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
…
1st Feb 2025
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment
Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
…
30th Jan 2025
Cetuximab: A Revolutionary Drug in Cancer Therapy
Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wo
…
29th Jan 2025
Tigatuzumab: Advancing Cancer Research with Targeted Therapies
Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
…
23rd Jan 2025
Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research
Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i
…
10th Dec 2024
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting
What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing canc
…
27th Nov 2024
Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research
Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.
…
27th Nov 2024
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond
What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
…
27th Nov 2024
Elotuzumab: Revolutionizing Multiple Myeloma Treatment and Research Applications
Quick Facts About ElotuzumabWhat is Elotuzumab?Elotuzumab is a monoclonal antibody designed to enhance the immune system's ability to detect and destroy multiple myeloma cells. It target
…
26th Nov 2024
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars
Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
…
26th Nov 2024
Daratumumab: Advancing Research in Multiple Myeloma and Beyond
Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
…
26th Nov 2024